Authors
Schäferhoff, Marco, Ramana, Gandham, Zimmerman, Armand, Fewer, Sara, Seiter, Andreas, Harimurti, Pandu, Sowers, Erin, Mutasa, Ronald
- Citation
- “ Schäferhoff, Marco ; Ramana, Gandham ; Zimmerman, Armand ; Fewer, Sara ; Seiter, Andreas ; Harimurti, Pandu ; Sowers, Erin ; Mutasa, Ronald . 2024 . Investing in Vaccine Security in the ASEAN Region . © Washington, DC: World Bank . http://hdl.handle.net/10986/41750 License: CC BY-NC 3.0 IGO . ”
- Collection(s)
- Health, Nutrition and Population (HNP) Discussion Papers
- Identifier externaldocumentum
- 34339978
- Identifier internaldocumentum
- 34339978
- Published in
- United States of America
- Report
- 191136
- Rights
- CC BY-NC 3.0 IGO
- Rights Holder
- World Bank
- Rights URI
- https://creativecommons.org/licenses/by-nc/3.0/igo
- UNIT
- Health Nutrition &Population EAP (HEAHN)
- URI
- https://hdl.handle.net/10986/41750
- date disclosure
- 2024-06-20
Files
Table of Contents
- Blank Page 50
- ASEAN Vaccine Security Study HNP Working Paper Technical Paper copyedited111123FINAL.pdf -1
- Rights and Permissions 4
- Table of Contents 7
- ACKNOWLEDGMENTS 8
- Introduction 9
- Methods and Data 10
- Overview of modeling approach 10
- Scenarios modeled 10
- Model specifications 12
- Data sources 14
- Results 17
- Scenario 1: Regional scenario Under the regional scenario, the development and manufacturing of vaccines would cost a total of US$2.7 billion, while the net benefits would amount to US$82.3 billion. As such, the benefit-cost ratio (BCR) amounts to 30.... 17
- Scenario 2: Regional pooled procurement scenario Under the regional pooled procurement scenario, the BCR is 35.09. This BCR is higher compared to Scenario 1 for two reasons: first, the vaccines are sold by the five focus countries, which generates an ... 18
- Scenario 3: National scenario Under the national scenario, the BCR is 9.51, a significantly smaller economic return compared with the regional scenarios above (Scenarios 1 and 2). In this scenario, cumulative benefits do not exceed cumulative costs un... 20
- Scenario 4: Pandemic outbreak scenario Under the pandemic outbreak scenario (a modification of the regional scenario that includes COVID-19), the development and manufacturing of vaccines would cost a total of US$3.2 billion, while the net benefits wo... 21
- Limitations 23
- Discussion 24
- References 27
- Appendices 30
- Blank Page 2
- Blank Page 51